Recombinant SATB2 antibody (AA 150-350)

Catalog No. ABIN7870945

The Rabbit Monoclonal anti-SATB2 antibody (Clone SATB2-8264R) (ABIN7870945) specifically detects SATB2 in WB and IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant SATB2 antibody (AA 150-350) (ABIN7870945)

Target: SATB2 (SATB Homeobox 2 (SATB2))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This SATB2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SATB2-8264R

Product Details anti-SATB2 Antibody

Binding Specificity: AA 150-350

Purpose: SATB2 Antibody

Purification: Protein A/G affinity

Immunogen: A recombinant partial protein sequence (within amino acids 150-350) from the human protein was used as the immunogen for the SATB2 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the SATB2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the SATB2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for SATB2

Target: SATB2 (SATB Homeobox 2 (SATB2))

Alternative Name: SATB2

Background: SATB2 is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.

UniProt: Q9UPW6